209 related articles for article (PubMed ID: 31924241)
21. CXCR1/2 inhibition blocks and reverses type 1 diabetes in mice.
Citro A; Valle A; Cantarelli E; Mercalli A; Pellegrini S; Liberati D; Daffonchio L; Kastsiuchenka O; Ruffini PA; Battaglia M; Allegretti M; Piemonti L
Diabetes; 2015 Apr; 64(4):1329-40. PubMed ID: 25315007
[TBL] [Abstract][Full Text] [Related]
22. Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia.
Leitner JM; Mayr FB; Firbas C; Spiel AO; Steinlechner B; Novellini R; Jilma B
Int J Immunopathol Pharmacol; 2007; 20(1):25-36. PubMed ID: 17346425
[TBL] [Abstract][Full Text] [Related]
23. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
[TBL] [Abstract][Full Text] [Related]
24. Reduction of NETosis by targeting CXCR1/2 reduces thrombosis, lung injury, and mortality in experimental human and murine sepsis.
Alsabani M; Abrams ST; Cheng Z; Morton B; Lane S; Alosaimi S; Yu W; Wang G; Toh CH
Br J Anaesth; 2022 Feb; 128(2):283-293. PubMed ID: 34893315
[TBL] [Abstract][Full Text] [Related]
25. Axillary Skip Metastases and the False-Negative Rate of Sentinel Lymph Node Biopsy in Patients With Breast Cancer Are Related to Negative ALDH-1 Expression and Ki-67 Expression.
Kim WG; Lee J
Int J Surg Pathol; 2017 Aug; 25(5):397-405. PubMed ID: 28145149
[TBL] [Abstract][Full Text] [Related]
26. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M
J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889
[TBL] [Abstract][Full Text] [Related]
27. CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Khan MN; Wang B; Wei J; Zhang Y; Li Q; Luan X; Cheng JW; Gordon JR; Li F; Liu H
Oncotarget; 2015 Aug; 6(25):21315-27. PubMed ID: 26087179
[TBL] [Abstract][Full Text] [Related]
28. The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells.
Koziel JE; Herbert BS
Breast Cancer Res Treat; 2015 Feb; 149(3):607-18. PubMed ID: 25627551
[TBL] [Abstract][Full Text] [Related]
29. СD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes.
Chekhun SV; Zadvorny TV; Tymovska YO; Anikusko MF; Novak OE; Polishchuk LZ
Exp Oncol; 2015 Mar; 37(1):58-63. PubMed ID: 25804234
[TBL] [Abstract][Full Text] [Related]
30. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
31. The chemokine receptors CXCR1/CXCR2 modulate antigen-induced arthritis by regulating adhesion of neutrophils to the synovial microvasculature.
Coelho FM; Pinho V; Amaral FA; Sachs D; Costa VV; Rodrigues DH; Vieira AT; Silva TA; Souza DG; Bertini R; Teixeira AL; Teixeira MM
Arthritis Rheum; 2008 Aug; 58(8):2329-37. PubMed ID: 18668539
[TBL] [Abstract][Full Text] [Related]
32. A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia.
Landoni G; Piemonti L; Monforte AD; Grossi P; Zangrillo A; Bucci E; Allegretti M; Goisis G; Gavioli EM; Patel N; De Pizzol M; Pasedis G; Mantelli F
Infect Dis Ther; 2022 Aug; 11(4):1559-1574. PubMed ID: 35618953
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer stem cells: we've got them surrounded.
Korkaya H; Wicha MS
Clin Cancer Res; 2013 Feb; 19(3):511-3. PubMed ID: 23251003
[TBL] [Abstract][Full Text] [Related]
34. Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment.
Kemp DM; Pidich A; Larijani M; Jonas R; Lash E; Sato T; Terai M; De Pizzol M; Allegretti M; Igoucheva O; Alexeev V
Oncotarget; 2017 Feb; 8(9):14428-14442. PubMed ID: 28129639
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer stem cell selectivity of synthetic nanomolar-active salinomycin analogs.
Huang X; Borgström B; Kempengren S; Persson L; Hegardt C; Strand D; Oredsson S
BMC Cancer; 2016 Feb; 16():145. PubMed ID: 26906175
[TBL] [Abstract][Full Text] [Related]
36. CXCR1/2 pathways in paclitaxel-induced neuropathic pain.
Brandolini L; Benedetti E; Ruffini PA; Russo R; Cristiano L; Antonosante A; d'Angelo M; Castelli V; Giordano A; Allegretti M; Cimini A
Oncotarget; 2017 Apr; 8(14):23188-23201. PubMed ID: 28423567
[TBL] [Abstract][Full Text] [Related]
37. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases.
Ha H; Debnath B; Neamati N
Theranostics; 2017; 7(6):1543-1588. PubMed ID: 28529637
[TBL] [Abstract][Full Text] [Related]
38. CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome.
Idowu MO; Kmieciak M; Dumur C; Burton RS; Grimes MM; Powers CN; Manjili MH
Hum Pathol; 2012 Mar; 43(3):364-73. PubMed ID: 21835433
[TBL] [Abstract][Full Text] [Related]
39. G31P, an antagonist against CXC chemokine receptors 1 and 2, inhibits growth of human prostate cancer cells in nude mice.
Liu X; Peng J; Sun W; Yang S; Deng G; Li F; Cheng JW; Gordon JR
Tohoku J Exp Med; 2012 Oct; 228(2):147-56. PubMed ID: 23019013
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype.
Ricardo S; Vieira AF; Gerhard R; Leitão D; Pinto R; Cameselle-Teijeiro JF; Milanezi F; Schmitt F; Paredes J
J Clin Pathol; 2011 Nov; 64(11):937-46. PubMed ID: 21680574
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
